Sam Brusco, Associate Editor03.09.22
Philips released new research evaluating mobile cardiac outpatient telemetry (MCOT) for first-line diagnostic ambulatory monitoring of 1,000 post-cryptogenic stroke patients for a year.
The study showed 30-day continuous monitoring with Philips’ BioTel Heart MCOT patch followed by an implantable loop recorder (ILR) improved atrial fibrillation (AFib) detection rate, spotting 4.6 times more patients with AFib than ILR alone. It also helped reduce secondary stroke risk from new anticoagulant use in patients with MCOT patch detected AFib.
The study also showed initial MCOT monitoring achieved almost eight times lower costs, reducing total cost per patient by $189,909 compared to only monitoring with ILR. Overall cost-of-care savings using the MCOT patch and ILR for undiagnosed AFib patients topped $4 million.
“The diagnostic tools clinicians use to monitor this group of patients play an important role in finding the cause of the stroke and developing a personalized treatment plan,” Andy Broadway, General Manager of Ambulatory Monitoring and Diagnostics at Philips told the press. “This new research confirms that using Philips BioTel Heart MCOT as the first line of evaluation is more cost-effective and can provide the level of diagnostic confidence needed to help detect and diagnose atrial fibrillation, and potentially prevent a second stroke.”
The study showed 30-day continuous monitoring with Philips’ BioTel Heart MCOT patch followed by an implantable loop recorder (ILR) improved atrial fibrillation (AFib) detection rate, spotting 4.6 times more patients with AFib than ILR alone. It also helped reduce secondary stroke risk from new anticoagulant use in patients with MCOT patch detected AFib.
The study also showed initial MCOT monitoring achieved almost eight times lower costs, reducing total cost per patient by $189,909 compared to only monitoring with ILR. Overall cost-of-care savings using the MCOT patch and ILR for undiagnosed AFib patients topped $4 million.
“The diagnostic tools clinicians use to monitor this group of patients play an important role in finding the cause of the stroke and developing a personalized treatment plan,” Andy Broadway, General Manager of Ambulatory Monitoring and Diagnostics at Philips told the press. “This new research confirms that using Philips BioTel Heart MCOT as the first line of evaluation is more cost-effective and can provide the level of diagnostic confidence needed to help detect and diagnose atrial fibrillation, and potentially prevent a second stroke.”